ABSTRACT
As an emerging tumor marker, the rarity and heterogeneity of circulating tumor cells (CTCs) increase the difficulty of detection. In recent years, CTCs enrichment technology based on biophysical, biochemical and microfluidic properties has been continuously developed, which has promoted the research and application of CTCs in malignant tumors diagnosis, clinical treatment and prognosis evaluation. Although there are still some deficiencies in the detection of CTCs, with the interdisciplinary integration, CTCs will play increasingly important roles in the diagnosis and treatment of malignant tumors.
ABSTRACT
There are many ways to identify circulating tumor cells in the current.Fluorescence has a wide range of applications in the identification of circulating tumor cells.The labeled cells can be observed and counted more intuitively by labeling the tumor cells with fluorescent group containing antibodies,probes and aptamers,and cytokine,CD45 and fluorescence in situ hybridization are widely used in the identification of various circulating tumor cell related tests.In recent years,people have explored the feasibility of using fluorescent probes to directly identify circulating tumor cells.With the development of biopsy probes and optical sectioning imaging technology of confocal microscopy,it is possible to directly identify circulating tumor cells with fluorescent probes in the future.
ABSTRACT
The incidence of gastric cancer ranks the fourth in all kinds of cancers in the world,ranking the second among patients with cancer-related deaths.The 5-year survival rate of gastric cancer patients is less than 30％.About 50％ of gastric cancer patients have recurred or metastasized after curative resection.Metastasis and recurrence are the major causes of death in cancer patients.CTCs play an important role in tumor metastasis.At present,there are more than 10 kinds of detection methods for CTCs in gastric cancer.The most widely used methods are RT-PCR,FCM,CelLTracks(R) AutoPrep(R) system and ISET.Recent studies have shown that CTCs in peripheral blood of patients with gastric cancer can be used to determine the clinical stage of patients,assess the prognosis and guide the individualized treatment of cancer.
ABSTRACT
Objective To study and analyze the efficacy and adverse reactions of beraprost sodium combined with aspirin in the treatment of diabetic foot.Methods 90 cases with diabetic foot were selected and they were randomly divided into the observation group and control group,35 cases in each group.Two groups were both treated with basic treatment.On the basis of the basic treatment,the control group was given aspirin,while the observation group was treated with beraprost sodium combined with aspirin.The clinical efficacy,ulcer healing rate,ankle back index,transcutaneous oxygen pressure,average healing time and the occurrence of adverse reactions were compared between the two groups.Results The clinical effective rate of the observation group was 93.3％ (42/45),which was significantly higher than 84.4％ (38/45) of the control group,the difference between the two groups was statistically significant (x2 =8.030,P ＜ 0.05).The wound healing rate,ankle dorsal index,average healing time,the degree of improvement of transcutaneous and oxygen pressuer of the observation group were (81.4 ± 2.7) ％,(11.2 ± 2.1),(39.1 ± 2.1) d and (26.3 ± 1.8) mmHg,which were significantly better than (69.3 ± 1.9) ％,(8.4 ± 2.9) ％,(52.3 ± 8.2) d and (16.3 ± 2.6)mmHg of the control group.The differences of these indicators between the two groups were statistically significant(t =12.72,7.92,12.06,9.97,P ＜ 0.05).The difference of adverse reactions between the two groups was not statistically significant (P ＞ 0.05).Conclusion Beraprost sodium combined with aspirin has better clinical efficacy in the treatment of diabetic foot.It can improve the patients'ulcer healing rate,the ankle back index,transcutaneous oxygen pressure,shorter the average healing time,and it has few adverse reactions.